Aytu BioPharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Aytu BioPharma generated cash of -$1,388,000, which is more than the previous year. Cash used in financing activities reached the amount of -$1,262,000 last year. Net change in cash is therefore -$2,979,000.
Cash Flow
| 2015 | -6.63M | -1.00M | 12.35M |
|---|---|---|---|
| 2016 | -10.65M | -5.30M | 16.66M |
| 2017 | -13.82M | -3.53M | 10.18M |
| 2018 | -15.94M | -484.29K | 22.65M |
| 2019 | -13.83M | -1.06M | 19.07M |
| 2020 | -28.37M | -5.65M | 71.06M |
| 2021 | -25.96M | -2.78M | 30.31M |
| 2022 | -28.82M | -3.24M | 1.53M |
| 2023 | -5.12M | -117K | 8.87M |
| 2024 | -1.38M | -329K | -1.26M |
AYTU Cash Flow Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 22.98M | 19.36M | 49.90M | 48.33M | 11.29M | 7.11M | 877.54K | 8.05M | 7.35M | 2.63M |
Operating activities | ||||||||||
Net income | -15.84M | -17.05M | -110.17M | -58.28M | -13.62M | -27.13M | -10.18M | -22.50M | -28.18M | -7.72M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 8.27M | 8.81M | 10.25M | 9.20M | 6.24M | 2.72M | 2.59M | 4.36M | 874.78K | 118.20K |
Stock-based compensation expense | 2.91M | 6.04M | 5.24M | 3.57M | 1.07M | 1.02M | 0 | 2.50M | 902.94K | 1.01M |
| Deferred income tax benefit | 2.91M | 6.04M | 5.24M | 3.57M | 1.07M | 1.02M | 0 | 2.50M | 902.94K | 1.01M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 5.32M | -7.15M | 6.53M | 1.54M | -3.56M | -1.16M | -50.74K | -355.03K | -5.36K | -157.05K |
Inventories | 2.27M | -3.60M | 1.29M | 2.78M | -6.95M | -101.09K | -26.75K | 195.42K | -485.26K | -39.44K |
Accounts payable | -2.87M | 2.38M | -7.68M | -3.24M | -1.37M | 134.77K | -109.70K | 493.21K | 1.62M | 547.31K |
Cash generated by operating activities | -1.38M | -5.12M | -28.82M | -25.96M | -28.37M | -13.83M | -15.94M | -13.82M | -10.65M | -6.63M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 91.86K | -2.01M | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | -2.34M | 0 | -59.84K | -74.70K | -111.60K | -2.25M | 0 |
Acquisitions Net | 0 | -5K | -3.17M | -2.82M | 188.22K | -505.02K | -7.38K | -4.03M | -3.05M | -1M |
Cash generated by investing activities | -329K | -117K | -3.24M | -2.78M | -5.65M | -1.06M | -484.29K | -3.53M | -5.30M | -1.00M |
Financing activities | ||||||||||
Common Stock Issued | 3.46M | 15.57M | 11.69M | 40.14M | 48.08K | 11.69K | 248.41K | 9.34M | 12.72M | 5M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -904.91K | 0 |
Repayments of term debt | -1.89M | -96K | -5.22M | -968K | -19.43M | 5M | 0 | 0 | -4.84M | 0 |
Cash used in financing activities | -1.26M | 8.87M | 1.53M | 30.31M | 71.06M | 19.07M | 22.65M | 10.18M | 16.66M | 12.35M |
Net Change In Cash | -2.97M | 3.62M | -30.54M | 1.56M | 37.03M | 4.18M | 6.23M | -7.17M | 701.12K | 4.71M |
Cash at end of period | 20.00M | 22.98M | 19.36M | 49.90M | 48.33M | 11.29M | 7.11M | 877.54K | 8.05M | 7.35M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |